Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
FO-Curtain Series (P10.4,P12.5,P15.6,P25,P31.2)(500×1000mm)
Contact UsLED Curtain Display-P10.4, P12.5, P15.6, P25, P31.2
-
Paclitaxel for Injection(Albumin-Bound)
Contact UsAlbumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility
-
Metal casings
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
Deye SUN-8K-G06P3-EU-AM2-P1
Contact Us2 MPP trackers, Max.effciency up to 98.5%
Zero export application,VSG application
String intelligent monitoring (optional)
Wide output voltage range
Anti-PlD function (Optional)
Reviews
There are no reviews yet.